Condition
Dry Macular Degeneration
Total Trials
6
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 1 (1)
P 2 (1)
Trial Status
Unknown3
Withdrawn2
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT02684578Phase 2Completed
Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD
NCT03688243UnknownPrimary
Non Exudative AMD Imaged With SS-OCT
NCT04469140UnknownPrimary
Non Exudative AMD Imaged With SS-OCT- Extension
NCT02590692Phase 1UnknownPrimary
Study of Subretinal Implantation of Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry AMD
NCT02699216Not ApplicableWithdrawnPrimary
BioCurrent Electrical Stimulation for the Treatment of Dry ARMD
NCT02024269Not ApplicableWithdrawnPrimary
Study to Assess the Safety and Effects of Cells Injected Intravitreal in Dry Macular Degeneration
Showing all 6 trials